Navigation Links
Allegheny Health Network Allergist Opposes OTC Sales of Corticosteroids in FDA Testimony, Citing Safety Concerns
Date:7/31/2013

Silver Spring, Md. (PRWEB) July 31, 2013

David P. Skoner, MD, Director of the Division of Allergy, Asthma and Immunology, Department of Medicine at Allegheny General Hospital (AGH), will testify today before the U.S. Food and Drug Administration in opposition to making triamcinolone acetonide nasal spray available over the counter. Currently, triamcinolone acetonide nasal spray is available only by prescription.

Dr. Skoner was chosen to represent the positions of both the American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) in recommending against over-the-counter sales of triamcinolone acetonide nasal spray (brand names include Nasacort) due to safety concerns.

Corticosteroids hold the potential for causing adverse effects on a patient’s eyes, bones, hypothalamic-pituitary-adrenal glands, and to stunt a child’s growth, Dr. Skoner said. The effects can be insidious and not noticed for several years. In addition, Dr. Skoner said, patients could have access to corticosteroids in other forms, raising the potential for adverse effects. The effect of combining inhaled nasal corticosteroids with other inhaled steroids has not been studied.

Drug manufacturer Sanofi-Aventis US has asked the FDA for permission to sell triamcinolone acetonide nasal spray over the counter. It is used to relieve the symptoms of hay fever or other upper respiratory allergies, including nasal congestion, runny nose, sneezing and itching.

The most recent research shows that intranasal corticosteroids can stunt a child’s growth, but the long-term effects, including the child’s final adult height, are unknown, Dr. Skoner said.

The AAAAI and ACAAI recommend using triamcinolone acetonide only under the supervision of an appropriately trained medical provider, Dr. Skoner said. He reviewed the case of a 6-year-old girl who used both inhaled and inhaled-nasal corticosteroids to treat cough and allergies to tree and grass pollen, mold and dust mites. Over a period of time, the treatment suppressed her adrenal function and she nearly died of an infection and hypotension.

“Photos of this child tell an unbelievable story, showing steadily progressive changes in physical appearance as a result of hypercorticism,” Dr. Skoner said. Direct quotes from her mother were: “Truly unbelievable if this drug makes it over the counter!” and “My child will need to be on growth hormone shots every day until she goes through puberty, as a result of her growth suppression that never corrected itself.”

“The decision to switch inhaled nasal corticosteroids to over-the-counter status will undoubtedly cause growth and adrenal suppression in a large number of children,” Dr. Skoner said. “The correct monitoring of these drugs’ systemic effects, and needed adjustment of dosing, can only be done in a health care setting.”

Read the full story at http://www.prweb.com/releases/2013/7/prweb10984638.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study by Allegheny General Hospital Physicians Shows Oral Immunotherapy is a Safe, Effective Alternative to Allergy Shots for Ragweed Sufferers
2. West Penn Allegheny Health System is First in Pennsylvania to Perform Groundbreaking Minimally-Invasive Procedure for Swallowing Disorder
3. West Penn Allegheny Health System Physicians Pinpoint Gastroesophageal Reflux Disease (GERD) as a Factor That May Cause Chronic Cough
4. You Survived Cancer: Now Pay Attention to Your Overall Health
5. NIH awards $20 million over 5 years to train next generation of global health researchers
6. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
7. Esophageal Cancer Surgery Can Leave Lingering Health Problems, Study Says
8. Climate Change Could Be Tough on Seniors Health: Study
9. Supporting LGB children may influence their long-term health, BU study finds
10. U.S. Spends Too Little on Public Health Initiatives: Report
11. Optimal care of bariatric surgery patients vital for long-term health and well-being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
Breaking Medicine Technology: